Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
The world's second-largest company in the healthcare equipment and supplies industry, Intuitive Surgical NASDAQ: ISRG, just reported Q2 financials. The results were solid, but not enough to move shares higher.
Intuitive Surgical's second-quarter results reflect a healthy demand for procedures on higher system utilization. However, tariffs lead to a decline in the gross margin outlook.
Intuitive Surgical, Inc. (NASDAQ:ISRG ) Q2 2025 Earnings Conference Call July 22, 2025 4:30 PM ET Company Participants David J. Rosa - CEO & Director Jamie E.
The headline numbers for Intuitive Surgical (ISRG) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Intuitive Surgical, Inc. (ISRG) came out with quarterly earnings of $2.19 per share, beating the Zacks Consensus Estimate of $1.92 per share. This compares to earnings of $1.78 per share a year ago.
Intuitive Surgical's premium valuation is justified by consistent mid-teens growth, a dominant market position, and a resilient razor-and-blade business model. Recent innovations like telesurgery and regulatory approvals further expand the company's total addressable market and reinforce its competitive moat. Risks include potential tariff impacts and capital return missteps, but a strong balance sheet and recurring revenues mitigate these concerns.
As robotic-assisted surgery continues its rising adoption in modern medicine, two industry leaders — Intuitive Surgical ISRG and Stryker SYK — are shaping the future of robotic-assisted surgery. Intuitive, renowned for its da Vinci Surgical System, continues to dominate the soft tissue surgery space.
Intuitive Surgical's second-quarter results are likely to reflect solid performance in the company's Instruments & Accessories segment. Improving margins buoy optimism.
Intuitive Surgical wins FDA nod for its Vessel Sealer Curved, boosting the da Vinci system's precision and multifunctional capabilities.
Besides Wall Street's top-and-bottom-line estimates for Intuitive Surgical (ISRG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.